Market Overview

Piper Jaffray Goes Overweight Sarepta, Expects FDA To Accept Next Key Drug Filing

Sarepta Says FDA Postpones Advisory Committee Meeting to Review Eteplirsen Due to Severe Weather Storm in the Washington D.C.
Related BMRN
Why Leerink Adjusted Upside Expectations For 3 Biotechs
Biomarin Pharmaceutical Q4 Earnings Outlook
Your Daily Pharma Scoop: Clovis Oncology Gets A Boost, Mesoblast Positive Data, Kadmon's Updated Results (Seeking Alpha)

  • Shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) have risen over 132 percent, year to date, reaching a peak on August 17, of $36.39.
  • Piper Jaffray’s Edward A. Tenthoff has upgraded Sarepta Therapeutics to Overweight, while raising the price target from $28 to $48.
  • Tentoff expects the FDA to accept the company’s NDA filing for eteplirsen when the 60-day review period ends on August 25.

Sarepta Therapeutics had held a pre-NDA meeting with the FDA in May for its exon 51 skipping drug, eteplirsen, for the treatment of Duchenne Muscular Dystrophy (DMD). Tentoff belives that the company has fulfilled all requests for information from the FDA since then.

A joint AdCom is expected for both eteplirsen and the exon 51 skipping drug developed by BioMarin Pharmaceutical, Inc. (NASDAQ: BMRN) to be tentatively scheduled for the third week of November.

According to the Morgan Stanley report, “Sarepta previously indicated that its data from fourth biopsies, and 192-week data would be submitted to the FDA and expects these data to be made public before the AdCom.”

Eteplirsen had received Rare Pediatric Disease Designation from the FDA last week, and is on a fast-track status. Tentoff believes that this implies that its PDUFA date could be in late February 2016, while drisapersen’s PDUFA date is scheduled for December 27.

The FDA filings for eteplirsen are based on the Phase IIb “201” and open label, extension “202” studies. The data from these trials show that the drug led to “prolonged periods of stability. Importantly, early treatment produced a significant benefit in 6MWT distance compared to patients receiving delayed treatment out to week 168,” Tentoff reported.

Sarepta Therapeutics is also running several ongoing trials on ambulatory and non-ambulatory exon 51 DMD boys, as well as studies on ambulatory exon 53 boys in Europe.

Posted-In: Analyst Color Biotech Long Ideas Upgrades Price Target Analyst Ratings Trading Ideas General


Related Articles (BMRN + SRPT)

View Comments and Join the Discussion!